Literature DB >> 22121887

Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer.

X B D'Journo1, M Ouattara, A Loundou, D Trousse, L Dahan, T Nathalie, C Doddoli, J F Seitz, P-A Thomas.   

Abstract

Malnutrition is common 1 year after esophageal cancer surgery. However, the prognostic impact of this malnutrition on long-term outcome has been poorly reported. This study aims at determining the potential effect on disease-free survival (DFS) of weight loss observed at 1 year in disease-free survivors after curative esophageal resection. From a prospective single-institution database, 304 patients having undergone a transthoracic esophagectomy with two-field lymphadenectomy and gastric reconstruction between 1996 to 2008 were identified. Patients who died during the postoperative course (n= 24), patients who died within the first postoperative year (n= 12), patients who presented with an early recurrence within the first postoperative year (n= 20), and those who were lost to follow-up (n= 22) were excluded from the study, as well as those for whom the follow-up was shorter than 1 year (n= 21). The remaining 205 patients constituted a homogeneous group of 1-year disease-free survivors after full postoperative work-up and formed the material of the present study. Body weight (BW) values were collected before any treatment at the onset of symptoms (initial BW) and 1 year after esophagectomy. A 1-year weight loss (1-YWL) exceeding 10% of the initial BW defined an important malnutrition. Impact of the 1-YWL ≥ or <10% of the initial BW on DFS was investigated. Logistic regression was performed to identify factors affecting DFS. The mean initial BW was 69.1 ± 12 kg, corresponding to a mean body mass index (BMI) of 23.8 ± 3 kg/m(2) . Preoperatively, 32 (15%) patients were in the underweight category (BMI < 20 kg/m2), 110 (54%) were in normal (BMI = 20-24 kg/m2), and 63 (31%) were in the overweight category (BMI ≥ 25 kg/m2). Mean 1-year BW was 63.5 ± 12 kg. 1-YWL was <10% of the initial BW in 92 patients (45%) and ≥ 10% in 113 patients (55%). Accordingly, 5-year DFS rates were 66% (median: 80 months) and 48% (median: 51 months), respectively (P= 0.005). On multivariate analysis, only three independent variables affected the DFS significantly: clinical N stage (cN) status (P= 0.007; odds ratio: 1.99, 1.2-3.3), incomplete resection (P= 0.008, OR: 3.6, 1.3-9.3), and 1-YWL ≥ 10% (P= 0.004, OR: 2.1: 1.2-3.4). 1-YWL of or exceeding 10% of the initial BW in 1-year disease-free survivors has a negative prognostic impact on DFS after esophagectomy for cancer. This information offers another view on the objectives of the perioperative nutritional care of these patients. Special vigilance program on the nutritional status in post-esophagectomy patients should be the rule.
© 2011 Copyright the Authors. Journal compilation © 2011, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Year:  2011        PMID: 22121887     DOI: 10.1111/j.1442-2050.2011.01282.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  16 in total

1.  Postoperative change of the psoas muscle area as a predictor of survival in surgically treated esophageal cancer patients.

Authors:  Seong Yong Park; Joon-Kee Yoon; Su Jin Lee; Seokjin Haam; Joonho Jung
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

Review 2.  Nutrition therapy issues in esophageal cancer.

Authors:  Keith R Miller; Matthew C Bozeman
Journal:  Curr Gastroenterol Rep       Date:  2012-08

3.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

4.  Routine jejunostomy tube feeding following esophagectomy.

Authors:  Teus J Weijs; Hanneke W J van Eden; Jelle P Ruurda; Misha D P Luyer; Elles Steenhagen; Grard A P Nieuwenhuijzen; Richard van Hillegersberg
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 5.  Cachexia in patients with oesophageal cancer.

Authors:  Poorna Anandavadivelan; Pernilla Lagergren
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

6.  Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients.

Authors:  S Shen; J L Araujo; N K Altorki; J R Sonett; A Rodriguez; K Sungur-Stasik; C F Spinelli; A I Neugut; J A Abrams
Journal:  Dis Esophagus       Date:  2017-09-01       Impact factor: 3.429

7.  Risk Factors for Weight Loss 1 Year After Esophagectomy and Gastric Pull-up for Esophageal Cancer.

Authors:  Seong Yong Park; Dae Joon Kim; Jee Won Suh; Go Eun Byun
Journal:  J Gastrointest Surg       Date:  2018-04-02       Impact factor: 3.452

8.  Utility of feeding jejunostomy in patients with esophageal cancer undergoing esophagectomy with a high risk of anastomotic leakage.

Authors:  Weitao Zhuang; Hansheng Wu; Huiling Liu; Shujie Huang; Yinghong Wu; Cheng Deng; Dan Tian; Zihao Zhou; Ruiqing Shi; Gang Chen; Guillaume Piessen; Puja G Khaitan; Kazuo Koyanagi; Soji Ozawa; Guibin Qiao
Journal:  J Gastrointest Oncol       Date:  2021-04

9.  Excessive Pretreatment Weight Loss Is a Risk Factor for the Survival Outcome of Esophageal Carcinoma Patients Undergoing Radical Surgery and Postoperative Adjuvant Chemotherapy.

Authors:  Xiao-Li Yu; Jin Yang; Ting Chen; Yi-Min Liu; Wei-Ping Xue; Ming-Hui Wang; Shou-Min Bai
Journal:  Can J Gastroenterol Hepatol       Date:  2018-01-28

Review 10.  A systematic review of the nutritional consequences of esophagectomy.

Authors:  Melanie Baker; Vanessa Halliday; Robert N Williams; David J Bowrey
Journal:  Clin Nutr       Date:  2015-09-12       Impact factor: 7.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.